Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebulization by urinary monitoring

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 2, 2006, Pages 199-207

  Reychler, Gregory ^a   Wallemacq, P ^a   Rodenstein, D O ^a   Cumps, J ^a   Leal, T ^a   Liistro, G ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Amikacin; Intrapulmonary percussive ventilation; Lung deposition; Nebulization; Output; Urine

Indexed keywords

AMIKACIN;

ADULT; ARTICLE; BREATHING RATE; DEVICE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; INTRAPULMONARY PERCUSSIVE VENTILATION; JET NEBULIZATION; MALE; MEDICAL NEBULIZER; NEBULIZATION; NORMAL HUMAN; OUTCOME ASSESSMENT; PHYSIOTHERAPY; URINALYSIS;

ADMINISTRATION, INHALATION; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; HUMANS; LUNG; MALE; MONITORING, PHYSIOLOGIC; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY VENTILATION; SPIROMETRY; VENTILATORS, MECHANICAL;

EID: 33745629370     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.199     Document Type: Article

References (40)

1. Wales, D., H. Makker, J. Kane, et al. 1999. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 115:1278-1284.
2. Geddes, D.M. 1997. Nebulized therapy and cystic fibrosis. Eur. Respir. Rev. 7:173-176.
3. Touw, D.J., R.W. Brimicombe, M.E. Hodson, et al. 1995. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 8:1594-1604.
4. Loffert, D.T., D. Ikle, and H.S. Nelson. 1994. A comparison of commercial jet nebulizers. Chest 106:1788-1792.
5. Newman, S.P., G. Woodman, and S.W. Clarke. 1988. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax 43:318-322.
6. Kendrick, A.H., E.C. Smith, and R.S. Wilson. 1997. Selecting and using nebuliser equipment. Thorax 52:592-101.
7. PrEN 13544-1. 2001. Respiratory therapy equipment. Part 1: Nebulizing systems and theirs composants. European Standard.
8. Dequin, P.F., F. Faurisson, E. Lemarie, et al. 2001. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur. Respir. J. 18:316-322.
9. Ilowite, J.S., J.D. Gorvoy, and G.C. Smaldone. 1987. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 136:1445-1449.
10. Palmer, L.B., G.C. Smaldone, S.R. Simon, et al. 1998. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit. Care Med. 26:31-39.
11. Vecellio, N.L., D. Grimbert, J. Bordenave, et al. 2004. Residual gravimetric method to measure nebulizer output. J. Aerosol Med. 17:63-71.
12. Asmus, M.J., G. Milavetz, A.L. Tice, et al. 2001. In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers. Pharmacotherapy 21:534-539.
13. Coates, A.L., P.D. Allen, C.F. MacNeish, et al. 2001. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 119:1123-1130.
14. Faurisson, F., J.F. Dessanges, A. Grimfeld, et al. 1996. Etude comparative sur les performances et l'ergonomie de nebuliseurs dans la mucoviscidose [Comparative study of the performance and ergonomics of nebulizers in cystic fibrosis]. Rev. Mal. Respir. 13:155-162.
15. Newman, S.P. 2000. Lung deposition from nebulizers. Eur. Respir. Rev. 10:224-227.
16. Thomas, S.H., M.J. O'Doherty, A. Graham, et al. 1991. Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax 46:717-721.
17. Homnick, D.N., F. White, and C. de Castro. 1995. Comparison of effects of an intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy in treatment of cystic fibrosis. Pediatr. Pulmonol. 20:50-55.
18. Bird, F. 1978. Intrapulmonary percussive ventilation (IPV). Flying Physcian 30:4-8.
19. Natale, J.E., J. Pfeifle, and D.N. Homnick. 1994. Comparison of intrapulmonary percussive ventilation and chest physiotherapy. A pilot study in patients with cystic fibrosis. Chest 105:1789-1793.
20. American Thoracic Society. 1995. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am. J. Respir. Crit Care Med. 152:1107-1136.
21. Clark, A. and L. Borgstrom. 2002. In vitro testing of pharmaceutical aerosol and predicting lung deposition from in vitro measurements. In H. Bisgaard, C. O'Callaghan, and G.C. Smaldone, eds. Drug Delivery to the Lung. Marcel Dekker, New York, 105-142.
22. Konno, K., and J. Mead. 1967. Measurement of the separate volume changes of rib cage and abdomen during breathing. J. Appl. Physiol 22:407-422.
23. Dolovich, M.B., D. Killian, R.K. Wolff, et al. 1977. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am. Rev. Respir. Dis. 115:397-402.
24. Geller, D.E., H. Eigen, S.B. Fiel, et al. 1998. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr. Pulmonol. 25:83-87.
25. Meier, R., G.L. Hall, F.H. Sennhauser, et al. 2001. Wearing a noseclip improves nebulised aerosol delivery. Swiss Med. Wkly. 131:495-497.
26. Kohler, E., V. Sollich, R. Schuster-Wonka, et al. 2004. Does wearing a noseclip during inhalation improve lung deposition? J. Aerosol Med. 17:116-122.
27. Neale, M.G., K. Brown, R.W. Hodder, et al. 1986. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br. J. Clin. Pharmacol. 22:373-382.
28. Hakkinen, A.M., H. Uusi-Heikkila, M. Jarvinen, et al. 1999. The effect of breathing frequency on deposition of drug aerosol using an inhalation- synchronized dosimeter in healthy adults. Clin. Physiol. 19:269-274.
29. Reychler, G., A. Keyeux, C. Cremers, et al. 2004. Comparison of lung deposition in two types of nebulization: intrapulmonaiy percussive ventilation vs. jet nebulization. Chest 125:502-508.
30. O'Callaghan, C., and P.W. Barry. 1997. The science of nebulised drug delivery. Thorax 52:S31-S44.
31. Melchor, R., M.F. Biddiscombe, V.H. Mak, et al. 1993. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511.
32. Cooney, G.F., B.L. Lum, M. Tomaselli, et al. 1994. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 34:255-259.
33. Matthay, M.A. 1994. Function of the alveolar epithelial barrier under pathologic conditions. Chest 105:675-745.
34. Goldstein, I., F. Wallet, A. Nicolas-Robin, et al. 15-11-2002. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 166:1375-1381.
35. Schmekel, B., J.A. Bos, A.R. Khan, et al. 1992. Integrity of the alveolar-capillary barrier and alveolar surfactant system in smokers. Thorax 47:603-608.
36. Ramsey, B.W., H.L. Dorkin, J.D. Eisenberg, et al. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328:1740-1746.
37. MacLusky, I.B., R. Gold, M. Corey, et al. 1989. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Pulmonol. 7:42-48.
38. Finegold, S.M. 1959. Kanamycin. Arch. Intern. Med. 104:15-28.
39. Clarke, J.T., R.D. Libke, C. Regamey, et al. 1974. Comparative pharmacokinetics of amikacin and kanamycin. Clin. Pharmacol. Ther. 15:610-616.
40. Gyselynck, A.M., A. Forrey, and R. Cutler. 1971. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J. Infect. Dis. 124:6.